MARKET

VYGR

VYGR

Voyager Therapeutics Inc
NASDAQ
3.280
+0.030
+0.92%
After Hours: 3.280 0 0.00% 16:49 05/07 EDT
OPEN
3.240
PREV CLOSE
3.250
HIGH
3.320
LOW
3.170
VOLUME
324.92K
TURNOVER
0
52 WEEK HIGH
9.55
52 WEEK LOW
2.750
MARKET CAP
181.43M
P/E (TTM)
-2.9099
1D
5D
1M
3M
1Y
5Y
1D
Analysts Have Conflicting Sentiments on These Healthcare Companies: Omnicell (OMCL), Voyager Therapeutics (VYGR) and Masimo (MASI)
TipRanks · 10h ago
Voyager Therapeutics: Promising Future Prospects with Strong Financial Position and Innovative Pipeline
TipRanks · 10h ago
VOYAGER THERAPEUTICS INC <VYGR.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $12 FROM $13
Reuters · 17h ago
Voyager Therapeutics: Strong Financial Position and Promising Developmental Outlook Justify Buy Rating
TipRanks · 17h ago
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 23h ago
Voyager Therapeutics GAAP EPS of -$0.53 misses by $0.07, revenue of $6.47M misses by $7.08M
Seeking Alpha · 23h ago
VOYAGER THERAPEUTICS INC: ENDED Q1 WITH CASH POSITION OF $295 MLN WHICH WE EXPECT TO PROVIDE RUNWAY INTO MID-2027
Reuters · 1d ago
*Voyager Therapeutics 1Q Loss/Shr 53c >VYGR
Dow Jones · 1d ago
More
About VYGR
More
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
Recently
Symbol
Price
%Change

Webull offers Voyager Therapeutics Inc stock information, including NASDAQ: VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.